Literature DB >> 34826230

Radiological progression of extremity soft tissue sarcoma following pre-operative radiotherapy predicts for poor survival.

Christian Isaac1, John Kavanagh2, Anthony Michael Griffin1, Colleen I Dickie3, Rakesh Mohankumar2, Peter W Chung3, Charles N Catton3, David Shultz3, Peter C Ferguson1,4,5, Jay S Wunder1,4,5.   

Abstract

OBJECTIVES: To determine if radiological response to pre-operative radiotherapy is related to oncologic outcome in patients with extremity soft tissue sarcomas (STSs).
METHODS: 309 patients with extremity STS who underwent pre-operative radiation and wide resection were identified from a prospective database. Pre- and post-radiation MRI scans were retrospectively reviewed. Radiological response was defined by the modified Response Evaluation Criteria in Solid Tumours. Local recurrence-free, metastasis-free (MFS) and overall survival (OS) were compared across response groups.
RESULTS: Tumour volume decreased in 106 patients (34.3%; PR - partial responders), remained stable in 97 (31.4%; SD - stable disease), increased in 106 (34.3%; PD - progressive disease). The PD group were older (p = 0.007), had more upper extremity (p = 0.03) and high-grade tumours (p < 0.001). 81% of myxoid liposarcomas showed substantial decrease in size. There was no difference in initial tumour diameter (p = 0.5), type of surgery (p = 0.5), margin status (p = 0.4), or complications (p = 0.8) between the three groups. There were 10 (3.2%) local recurrences with no differences between the three response groups (p = 0.06). 5-year MFS was 52.1% for the PD group vs 73.8 and 78.5% for the PR and SD groups, respectively (p < 0.001). OS was similar (p < 0.001). Following multivariable analysis, worse MFS and OS were associated with higher grade, larger tumour size at diagnosis and tumour growth following pre-operative radiation. Older age was also associated with worse OS.
CONCLUSION: STS that enlarge according to Response Evaluation Criteria in Solid Tumour criteria following pre-operative radiotherapy identify a high risk group of patients with worse systemic outcomes but equivalent local control. ADVANCES IN KNOWLEDGE: Post-radiation therapy, STS enlargement may identify patients with potential for worse systemic outcomes but equivalent local control. Therefore, adjunct therapeutic approaches could be considered in these patients.

Entities:  

Mesh:

Year:  2021        PMID: 34826230      PMCID: PMC8822555          DOI: 10.1259/bjr.20210936

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  29 in total

1.  Adverse effect of older age on the recurrence of soft tissue sarcoma of the extremities and trunk.

Authors:  David J Biau; Peter C Ferguson; Robert E Turcotte; Peter Chung; Marc H Isler; Soha Riad; Anthony M Griffin; Charles N Catton; Brian O'Sullivan; Jay S Wunder
Journal:  J Clin Oncol       Date:  2011-09-19       Impact factor: 44.544

2.  Myxoid\round cell liposarcoma (MRCLS) revisited: an analysis of 418 primarily managed cases.

Authors:  Louis-Charles Moreau; Robert Turcotte; Peter Ferguson; Jay Wunder; Paul Clarkson; Bas Masri; Marc Isler; Norbert Dion; Joel Werier; Michelle Ghert; Benjamin Deheshi
Journal:  Ann Surg Oncol       Date:  2011-11-04       Impact factor: 5.344

3.  Complete pathologic response to neoadjuvant radiotherapy is predictive of oncological outcome in patients with soft tissue sarcoma.

Authors:  Dhruvil Shah; Dariusz Borys; Steve R Martinez; Chin-Shang Li; Robert M Tamurian; Richard J Bold; Arta Monjazeb; Robert J Canter
Journal:  Anticancer Res       Date:  2012-09       Impact factor: 2.480

4.  Internal fixation of radiation-induced pathological fractures of the femur has a high rate of failure.

Authors:  A Sternheim; K Saidi; J Lochab; P W O'Donnell; W C Eward; A Griffin; J S Wunder; P Ferguson
Journal:  Bone Joint J       Date:  2013-08       Impact factor: 5.082

5.  Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity.

Authors:  J C Yang; A E Chang; A R Baker; W F Sindelar; D N Danforth; S L Topalian; T DeLaney; E Glatstein; S M Steinberg; M J Merino; S A Rosenberg
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

6.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

Authors:  Haesun Choi; Chuslip Charnsangavej; Silvana C Faria; Homer A Macapinlac; Michael A Burgess; Shreyaskumar R Patel; Lei L Chen; Donald A Podoloff; Robert S Benjamin
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

7.  Phase 2 study of preoperative image-guided intensity-modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft tissue sarcoma.

Authors:  Brian O'Sullivan; Anthony M Griffin; Colleen I Dickie; Michael B Sharpe; Peter W M Chung; Charles N Catton; Peter C Ferguson; Jay S Wunder; Benjamin M Deheshi; Lawrence M White; Rita A Kandel; David A Jaffray; Robert S Bell
Journal:  Cancer       Date:  2013-02-19       Impact factor: 6.860

8.  Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas.

Authors:  Matthias R Benz; Martin S Allen-Auerbach; Fritz C Eilber; Hui J J Chen; Sarah Dry; Michael E Phelps; Johannes Czernin; Wolfgang A Weber
Journal:  J Nucl Med       Date:  2008-09-15       Impact factor: 10.057

9.  Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas; the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) and Imaging Group recommendations for radiological examination and reporting with an emphasis on magnetic resonance imaging.

Authors:  C Messiou; S Bonvalot; A Gronchi; D Vanel; M Meyer; P Robinson; C Morosi; J L Bloem; P H Terrier; A Lazar; C Le Péchoux; E Wardelman; J M Winfield; B Boulet; J Bovée; R L Haas
Journal:  Eur J Cancer       Date:  2016-01-20       Impact factor: 9.162

10.  Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.

Authors:  Penella J Woll; Peter Reichardt; Axel Le Cesne; Sylvie Bonvalot; Alberto Azzarelli; Harald J Hoekstra; Michael Leahy; Frits Van Coevorden; Jaap Verweij; Pancras C W Hogendoorn; Monia Ouali; Sandrine Marreaud; Vivien H C Bramwell; Peter Hohenberger
Journal:  Lancet Oncol       Date:  2012-09-04       Impact factor: 41.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.